Skip to main content
(352) 273-9400

Ginger Clark, MD, MS : Research

Gastroenterologist, Transplant Hepatologist

Photo of Ginger Clark
(352) 273-9400 MyUFHealth

Research at a glance

Top areas of exploration

  • Liver Cirrhosis , 8 publications
  • Hepatitis C , 8 publications
  • alpha 1-Antitrypsin Deficiency , 6 publications
  • Antiviral Agents , 6 publications

Research activity

42 publications

1,243 citations

Why is this important?

Active clinical trials

BIO89-100-132 The ENLIGHTEN-Cirrhosis Study

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).

Investigator
Ginger Clark
Status
Accepting Candidates
Ages
18 Years - 75 Years
Sexes
All
TAK-999-3003

The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who have taken part in previous fazirsiran studies (AROAAT2001…

Investigator
Ginger Clark
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All

My publications

42 publications

2024

Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.

Alimentary pharmacology & therapeutics

PubMed • Publisher's site

2021

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.

Journal of hepatology

PubMed • Publisher's site

2021

Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens.

PloS one

PubMed • Publisher's site